Bruker (BRKR) Tops Q2 EPS by 3c, Beats on Revenues; Offers FY17 EPS Guidance

Bruker (NASDAQ: BRKR) reported Q2 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $414.9 million versus the consensus estimate of $385.5 million.

Fiscal Year (FY) 2017 Financial Outlook

Bruker is adjusting its 2017 revenue growth and non-GAAP EPS outlook to reflect changes in foreign currency rates and the year-to-date performance. For FY 2017, the Company now expects revenue growth of 4.5% to 6.0%, including organic growth of 1.5% to 2.0%, growth from acquisitions of 3.5% to 4%, and a headwind from foreign currency rates of -0.5% to 0%.

The Company continues to project an increase in FY 2017 non-GAAP operating margin of 40 bps to 70 bps year-over-year, including approximately 40 bps of headwind from recent acquisitions. For FY 2017, Bruker now expects non-GAAP EPS of $1.08 to $1.12.

For the Company\'s outlook for FY 2017 non-GAAP operating margin and non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see \"Use of Non-GAAP Financial Measures\" below for a description of items excluded from our expected non-GAAP operating margin and non-GAAP EPS.

GUIDANCE:

Bruker sees Q3 2017 EPS of $1.08-$1.13, versus the consensus of $1.10.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• Opera Limited (OPRA) Misses Q1 EPS by 5c, provides guidance